human ifn γ elisa kit  (Elabscience Biotechnology)

Journal:

Article Title:

doi:

Figure Lengend Snippet: Effects of compounds on IFN‐γ release from Jurkat cells. All data are presented as the mean ± SD, n = 3. **** p < 0.0001, #### p < 0.0001. IFN‐γ, interferon‐γ.

Article Snippet: Then, above mixtures were cultured at 37°C for 24 h. After that time, the supernatants were diluted 1:1 and harvested for detection of lFN‐γ levels according to the manufacturer's protocol by using a human IFN‐γ ELISA Kit (Multi Sciences, catalog #EK180‐90).

Techniques:

Journal: Frontiers in Immunology

Article Title: Platform-based manufacturing of tumor-infiltrating lymphocytes derived from different solid tumor types

doi: 10.3389/fimmu.2026.1854761

Figure Lengend Snippet: Process development (PD) NTU101 and good manufacturing practice (GMP) NTU101 manufacturing quality criteria, including in-process controls (IPCs), release tests (RT), and sampling times.

Article Snippet: Secreted IFN-γ was quantified using reagents from, and a protocol based on, a human IFN-γ ELISA kit (Diaclone); this included the IFN-γ standards, antibody pair (capture and detection antibody), and horseradish peroxidase (HRP)-streptavidin, prepared as described in the kit’s protocol.

Techniques: Process/Product Development, Sampling, Enzyme-linked Immunosorbent Assay

Journal: Frontiers in Immunology

Article Title: Platform-based manufacturing of tumor-infiltrating lymphocytes derived from different solid tumor types

doi: 10.3389/fimmu.2026.1854761

Figure Lengend Snippet: Release test (RT) data for process development (PD) NTU101 drug products (DPs) per tumor type. (A) Cell viability (red dotted line: RT8 ≥ 70% viable cells), (B) Viable CD45+CD3+ cell percentage determined by flow cytometry (red dotted line: RT3 ≥ 90% Viable CD45+CD3+ cells of viable cells), (C) viable CD45+CD3+ cell number (red dotted line: RT9 ≥ 10×10^9 viable CD45+CD3+ cells), compensated for the reduced scale of PD runs compared to GMP NTU101 manufacturing (multiplied 20-fold, to compensate for the 1/20 th scale), (D) Potency (IFN-γ release upon CD3/CD28-polymer stimulation) (red dotted line: RT1 ≥ 1×10^3 pg/mL IFN-γ). Boxplots show the median and interquartile range (IQR); whiskers extend to 1.5 × IQR, and points beyond this range are shown as outliers. Individual observations per batch are overlaid as points. Statistical analysis was performed using ANOVA or the Kruskal-Wallis test, with Tukey’s honest significant difference (HSD) test and Dunn’s multiple comparisons test, respectively. When ANOVA or the Kruskal-Wallis tests were non-significant (ns; p≥0.05), ns was annotated for all multiple comparisons. ENDC, Endometrial carcinoma; NSCLC, Non-small cell lung cancer; PENC, Penile cancer.

Article Snippet: Secreted IFN-γ was quantified using reagents from, and a protocol based on, a human IFN-γ ELISA kit (Diaclone); this included the IFN-γ standards, antibody pair (capture and detection antibody), and horseradish peroxidase (HRP)-streptavidin, prepared as described in the kit’s protocol.

Techniques: Process/Product Development, Flow Cytometry, Polymer, Analysis

Journal: Frontiers in Immunology

Article Title: Platform-based manufacturing of tumor-infiltrating lymphocytes derived from different solid tumor types

doi: 10.3389/fimmu.2026.1854761

Figure Lengend Snippet: In vitro tumor-reactivity of process development NTU101 drug products (DPs). Cytotoxicity (relative cell killing) of CD45- target cells (T) within an autologous tumor digest, following co-culture with NTU101-DP effector cells (E) at increasing E:T ratios. Tumor digest alone (E:T = 0:1) serves as the negative control and internal standard. Cytotoxicity data for (A) Endometrial carcinoma (ENDC)-derived DPs, (B) Non-small cell lung cancer (NSCLC)-derived DPs, and (C) Penile cancer (PENC)-derived DPs. For greyed-out batches in the legend, there were insufficient viable cells available for co-culture or CD45- cells in the tumor digest. Fold increase of (absolute) IFN-γ concentration upon NTU101-DP cells (Responder; R) co-culture with tumor digest (Stimulator; S) in a 1:5 R:S ratio, compared to the highest concentration of NTU101-DP cells or tumor digest cells alone of (D) ENDC batches, (E) NSCLC batches, and (F) PENC batches. The gray dotted line represents the 1.5-fold increase in IFN-γ concentration required to identify tumor-reactive NTU101-DPs. The average of IFN-γ concentrations (pg/mL), measured in triplicate, is reported for each batch under the bar plots per condition. In both the line and bar plots, drug products considered tumor-reactive are outlined in black. In all panels, error bars represent the standard deviation of the replicates. For the NC condition, error bars represent the %CV of the NC replicates, which serves as the normalization reference for all other conditions. Darker markers and bars represent NTU101-DPs derived from mismatch repair-deficient and HPV-positive starting materials for ENDC and PENC, respectively, and NTU101-DPs derived from PD-L1-positive NSCLC starting materials. All tested NTU101-DPs were derived from NSCLC starting materials from smokers. In the enumeration of the tumor digest to determine E:T and R:S ratios, no distinction was made between viable tumor and non-tumor cells. Due to the presence of viable non-tumor cells in the tumor digest, the E:T and R:S cell ratios were likely higher than the reported ratios.

Article Snippet: Secreted IFN-γ was quantified using reagents from, and a protocol based on, a human IFN-γ ELISA kit (Diaclone); this included the IFN-γ standards, antibody pair (capture and detection antibody), and horseradish peroxidase (HRP)-streptavidin, prepared as described in the kit’s protocol.

Techniques: In Vitro, Process/Product Development, Co-culture Assay, Negative Control, Derivative Assay, Concentration Assay, Standard Deviation, Co-Culture

Journal: Frontiers in Immunology

Article Title: Platform-based manufacturing of tumor-infiltrating lymphocytes derived from different solid tumor types

doi: 10.3389/fimmu.2026.1854761

Figure Lengend Snippet: Release test data of GMP NTU101 batches.

Article Snippet: Secreted IFN-γ was quantified using reagents from, and a protocol based on, a human IFN-γ ELISA kit (Diaclone); this included the IFN-γ standards, antibody pair (capture and detection antibody), and horseradish peroxidase (HRP)-streptavidin, prepared as described in the kit’s protocol.

Techniques:

Journal: Frontiers in Immunology

Article Title: ESCO1 stabilizes NUFIP2 through acetylation–ubiquitination crosstalk to promote pancreatic cancer progression

doi: 10.3389/fimmu.2026.1929713

Figure Lengend Snippet: The ESCO1/NUFIP2 axis modulates antitumor immune responses in pancreatic cancer. (A, B) Correlations of ESCO1 and NUFIP2 expression with tumor-infiltrating immune cells. (C–F) Flow cytometric analysis of CD80, CD83, CD86, and HLA-DR expression in induced DCs. (G–L) IFN-γ secretion by CTLs stimulated with DCs pulsed with tumor lysates from PANC-1 and SW1990 cells subjected to ESCO1 or NUFIP2 knockdown, or ESCO1 knockdown combined with TSA treatment. ****P < 0.0001.

Article Snippet: After all samples had been collected, IFN-γ concentrations in the culture supernatants were measured using a Human IFN-γ ELISA Kit (Cat. No. KE00146, Proteintech Group, Inc., Wuhan, China) according to the manufacturer’s instructions.

Techniques: Expressing, Analysis, Knockdown

Journal: Cell Reports Medicine

Article Title: A biomimetic hybrid membrane vesicle nanoplatform attenuates tendinopathy through neuroinflammation modulation and tendon regeneration

doi: 10.1016/j.xcrm.2026.102937

Figure Lengend Snippet: MSM-DTM adsorbs inflammatory cytokines, suppresses TSPCs inflammation and senescence, and promotes tenogenic differentiation and migration (A) The remaining concentrations of TNF-α, IL-1β, IL-6, IFN-γ, LPS, and NGF were detected by ELISA after co-culture with different concentrations of MSM. (B and C) RT-qPCR of IL-6 and CCL-2 in TSPCs under different treatments. (D) Western blot of COL1A2, MMP3, and TNMD. (E) ELISA of TNF-α, IL-6, and IFN-γ in supernatants. (F)Western blot of p16 and p21 after 7 days of treatment. (G) β-Galactosidase staining analysis after 7 days of treatment. Scale bars, 100 μm. (H and I) Immunofluorescence and quantification of TNMD and TNC after 14-day treatment. Scale bars, 50 μm. (J) Relative mRNA expression of tenogenic differentiation markers SCX and TNC. (K and L) Representative images and quantification of Transwell assay. Scale bars, 100 μm. (M and N) Representative images and quantification of wound healing assay. Scale bars, 100 μm. Statistical comparisons were performed with one-way ANOVA with Tukey’s multiple comparisons test. Data are presented as the mean ± SD, n = 3. Ns, no significance, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 between groups.

Article Snippet: IFN-γ ELISA kit , ABclonal , RK00015.

Techniques: Migration, Enzyme-linked Immunosorbent Assay, Co-Culture Assay, Quantitative RT-PCR, Western Blot, Staining, Immunofluorescence, Expressing, Transwell Assay, Wound Healing Assay

Journal: Cell Reports Medicine

Article Title: A biomimetic hybrid membrane vesicle nanoplatform attenuates tendinopathy through neuroinflammation modulation and tendon regeneration

doi: 10.1016/j.xcrm.2026.102937

Figure Lengend Snippet:

Article Snippet: IFN-γ ELISA kit , ABclonal , RK00015.

Techniques: Recombinant, Lysis, Hydroxyproline Assay, Enzyme-linked Immunosorbent Assay, Isolation, SYBR Green Assay, Bicinchoninic Acid Protein Assay, Staining, Software